Alomfilimab
- CAS No.
- 2489390-15-8
- Chemical Name:
- Alomfilimab
- Synonyms
- KY-1044
- CBNumber:
- CB114297653
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
Alomfilimab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0626353 | KY-1044 99.51% | 2489390-15-8 | 1mg | $325 | 2026-06-04 | Buy |
| ChemScene | CS-0626353 | KY-1044 99.51% | 2489390-15-8 | 5mg | $812 | 2026-06-04 | Buy |
| ChemScene | CS-0626353 | KY-1044 99.51% | 2489390-15-8 | 10mg | $1300 | 2026-06-04 | Buy |
| aablocks | AA02E661 | KY-1044 >98% | 2489390-15-8 | 1mg | $369 | 2026-06-03 | Buy |
| aablocks | AA02E661 | KY-1044 >98% | 2489390-15-8 | 5mg | $869 | 2026-06-03 | Buy |
Alomfilimab Chemical Properties, Uses, Production
Uses
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOShigh cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8+ TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response[1].
in vivo
KY-1044 (Alomfilimab; SAR 445256; 10 mg/kg; ip; twice a week for 3 weeks) mIgG2a (effector enable) monotherapy blocks tumor growth in lymphoma/myeloma tumor models[1].
In syngeneic mouse tumor models, KY-1044 depletes ICOShigh Treg and increases the intratumoral TEff:Treg ratio, resulting in increased secretion of IFNγ and TNFα by TEff cells[1].
| Animal Model: | 8- to 10-week-old wild-type female Balb/C or C57BL/6J mice with A20 cells[1] |
| Dosage: | 200 μg (10 mg/kg) |
| Administration: | IP; twice a week for 3 weeks starting from 6 days following tumor cell implantation |
| Result: | Triggered an antitumor response, with more than 90% of the mice being free from measurable disease at the end of the study (day 42). |
References
[1] Richard C.A. Sainson, et al. An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression. Cancer Immunol Res. 2020 Dec;8(12):1568-1582. DOI:10.1158/2326-6066.CIR-20-0034
Alomfilimab Preparation Products And Raw materials
Raw materials
Preparation Products
Alomfilimab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
| Wanxin Biotechnology (Jiaxing) Co., LTD | 0573-83568680 18057391398 | 3956524501@qq.com | China | 1441 | 58 |
| Wuhan Maixi Biotechnology Co., Ltd | 18007167883 18007167883 | Service@mabnus.com | China | 921 | 58 |
